Histone deacetylase inhibitor suberoylanilide hydroxamic acid suppresses the pro-oncogenic effects induced by hepatitis B virus pre-S2 mutant oncoprotein and represents a potential chemopreventive agent in high-risk chronic HBV patients. [electronic resource]
Producer: 20130403Description: 475-85 p. digitalISSN:- 1460-2180
- Animals
- Apoptosis -- drug effects
- Blotting, Western
- COP9 Signalosome Complex
- Carcinoma, Hepatocellular -- etiology
- Cell Cycle -- drug effects
- Cell Nucleus -- drug effects
- Cell Proliferation -- drug effects
- Cyclin-Dependent Kinase Inhibitor p27 -- genetics
- Cytoplasm -- drug effects
- Female
- Fluorescent Antibody Technique
- Hepatitis B Surface Antigens -- genetics
- Hepatitis B virus -- drug effects
- Hepatitis B, Chronic -- complications
- Hepatocytes -- cytology
- Histone Deacetylase Inhibitors -- pharmacology
- Humans
- Hydroxamic Acids -- pharmacology
- Immunoenzyme Techniques
- Immunoprecipitation
- Intracellular Signaling Peptides and Proteins -- genetics
- Liver Neoplasms -- etiology
- Male
- Mice
- Mice, Inbred C57BL
- Mice, Transgenic
- Mutant Proteins -- genetics
- Mutation -- genetics
- Nuclear Proteins -- genetics
- Peptide Hydrolases -- genetics
- Protein Precursors -- genetics
- RNA, Messenger -- genetics
- Real-Time Polymerase Chain Reaction
- Reverse Transcriptase Polymerase Chain Reaction
- TATA Box Binding Protein-Like Proteins -- genetics
- Two-Hybrid System Techniques
- Vorinostat
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.